Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 4 Mar 2015

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Boehringer Ingelheim submitted idarucizumab for approval of marketing authorization to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canada. The submission is directed to patients who require rapid reversal of the anticoagulant effect of dabigatran, the active ingredient in Boehringer Ingelheim’s Pradaxa. Pradaxa, a direct thrombin inhibitor (DTI), was the first […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of its newest candidate, ALKS 7119, in the third quarter of 2015. ALKS 7119 has a multivalent mechanism of action […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Mar 2015

ICON Completes the Acquisition of MediMedia Pharma Solutions

ICON plc completed the acquisition of MediMedia Pharma Solutions, creating the industry’s leading integrated market access solution. Headquartered in Dublin, ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical […]

March 3, 2015 - 1 minutemin - By Lourdes Riquelme

Orca Pharmaceuticals AstraZeneca autoimmune2

News and Trends 27 Feb 2015

Orca Pharmaceuticas Associates with AstraZeneca to Identify Best-in-Class RORγ Inhibitors

Orca Pharmaceuticals, and AstraZeneca embarked on a three year collaboration to develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (RORγ). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, orally available and effective treatment. RORγ plays a key role in […]

February 27, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

SSB’s Ambr Bioreactor Systems Enhanced with Software for Design of Experiments

The French company, Sartorius Stedim Biotech (SSB), announced that the 2015 version of the Ambr systems (Ambr 15 and Ambr 250) will be supplied with integrated BioPAT MODDE Software for Design of Experiments (DoE), powered by Umetrics. This will allow bioprocess scientists to easily implement DoE into their work flow for simpler process optimization and […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

Celltrion launches world’s first biosimilar monoclonal antibody in 12 new European markets

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. The treatment to the treatment of autoimmune diseases is now available in 31 countries. Remsima, developed by the South Korean company Celltrion, is the world’s first biosimilar monoclonal […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Ferring Pharmaceuticals signed an agreement with South Korean CTCBIO to acquire rights to a novel oral drug delivery technology. The Swiss company is growing more and more rapidly with plenty of updates since the begining of the year. Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Feb 2015

Ipsen buys an option to Acquire Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS Ventures, may become part of Ipsen. The French giant payed €6M upfront for the option to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment […]

February 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 24 Feb 2015

Cobra Biologics and Manchester University Awarded €296.4K

The University of Manchester and Cobra Biologics, biologics and pharmaceuticals manufacturer, have been awarded €296.4K by Innovate UK and the Biotechnology and Biological Sciences Research Council (BBSRC). The project is one of the only 23 which will share almost €27.3M given away by the competition that intends to bring innovative biotechnology projects to market. The joint […]

February 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Feb 2015

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

Good news for diabetes mellitus type 2 patients, as Novo Nordisk announced positive results for phase II trial with oral semaglutide. Novo Nordisk successfully completed the phase II trial for OG217SC, an oral formulation of the longacting GLP-1 analogue semaglutide. Confirming the primary end-point of the trial, all doses of oral semaglutide were statistically significantly […]

February 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 Feb 2015

GNA Biosolutions Leads the Consortium for Ultra-Fast Detection of Ebola

The ultra-fast diagnostic instruments developer, GNA Biosolutions (GNA), started the FILODIAG (Filovirus Diagnostics) project for developing a high-speed Ebola detection system based on GNA’s novel Laser PCR technology. There is an urgent need for fast and accurate diagnostic tests in the current and any future Ebola crisis. The rapid diagnosis of Ebola during early and […]

February 20, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 19 Feb 2015

Lead Pharma partners with Sanofi to beat Autoimmune Diseases

Lead Pharma is a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer. It has entered into a research collaboration with big-shot Sanofi to develop small molecule therapies directed against the nuclear hormone receptor ROR gamma t (RORyt) to treat a broad range of autoimmune disorders. A big news for this Netherland-based Biotech […]

February 19, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Alkermes presents its new treatment of Alzheimer’s agitation

ICON Completes the Acquisition of MediMedia Pharma Solutions

Orca Pharmaceuticas Associates with AstraZeneca to Identify Best-in-Class RORγ Inhibitors

SSB’s Ambr Bioreactor Systems Enhanced with Software for Design of Experiments

Celltrion launches world’s first biosimilar monoclonal antibody in 12 new European markets

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Ipsen buys an option to Acquire Canbex

Cobra Biologics and Manchester University Awarded €296.4K

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

GNA Biosolutions Leads the Consortium for Ultra-Fast Detection of Ebola

Lead Pharma partners with Sanofi to beat Autoimmune Diseases

Subscribe to our newsletter to get the latest biotech news!